Advanced XFI: Invest in the Future of Imaging.
The advanced XFI imaging method by axiom insights aims to fundamentally transform drug development by enabling faster, cheaper, and more precise preclinical studies. For you as an investor or potential partner, this means the unique chance to benefit from the start. We invite you to join us on the journey to define a new global imaging standard.
you as an investor
Opportunity: Novelty Today — Standard Tomorrow.
Pharma companies spend billions each year on preclinical research. They face high costs, long timelines, and frequent late-stage failures, while killing billions of test animals every year. XFI by axiom solves these issues: it drastically reduces animal use, delivers new, invaluable insights, and accelerates decision-making. The demand for such a solution is immediate and global.
How Advanced XFI Changes The Rules
Massive Market Opportunity:
Immediate ROI:
Ethical and Regulatory Edge:
Scalable Across Industries:
Countless applications across oncology, immunology and food research.
High Entry Barriers:
“To the best of our knowledge, we are the only team worldwide to have solved a specific fundamental physical challenge underlying our technology.”
Traction & Proof
Impact That Matters
Advanced XFI by axiom insights is not only a business opportunity, but also an ethical innovation. By reducing animal use and aligning with the 3R principles, the method supports sustainability goals, strengthens ESG profiles, and improves regulatory acceptance worldwide.
Founded at DESY and Hamburg University (2019):
Spin-off from one of the world’s leading research centers for X-ray science.
Published in Scientific Reports (a Nature journal):
Validated at PETRA III:
Patents Secured:
Regulatory Validation:
Recognition & Partnerships:
Next Steps:
Business Model & Scaling Strategy
Today: Service-based revenue through preclinical imaging studies at DESY Hamburg.
Next: Expansion to additional synchrotron hubs across the globe, development of standardized protocols, and an AI-powered prediction system with licensing models.
Future: Establishment of dedicated XFI facilities and, ultimately, the translation of the method into safe in vivo human applications.
Partner With Us
Beyond investment, we welcome collaborations with pharma, biotech, CROs, and imaging companies to broaden XFI’s validation and expand its use cases. Together, we can develop standardized protocols, integrate the method into diverse workflows, and bring real-world impact to preclinical and clinical imaging alike. Let’s establish XFI as the next global benchmark in biomedical research.
Funding & Growth Outlook
We are raising capital to scale our operations, standardize procedures, expand our team, educate the industry, and drive adoption of our advanced XFI method. The funds will accelerate automation, AI-supported data analytics, and commercial partnerships with leading pharma, biotechnology companies.
Our goal is to establish XFI as a new standard in preclinical imaging, unlocking major recurring revenue streams and widespread adoption around the globe.
Our Team
axiom insights unites leading experts from physics, life sciences, and business — combining decades of experience in research, innovation, and technology transfer. Founded and operating within the renowned DESY research environment, the team has direct access to one of the most advanced synchrotron facilities and an exceptional global network. This unique combination of scientific expertise, interdisciplinary collaboration, and strategic vision builds the foundation for axiom insights‘ pioneering work.
